{
    "ticker": "NUVB.WS",
    "name": "Nuvation Bio Inc.",
    "description": "Nuvation Bio Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of cancer. Founded in 2018 and headquartered in New York, Nuvation Bio is dedicated to advancing innovative treatments that can significantly improve patient outcomes. The company\u2019s pipeline includes a range of drug candidates designed to target various cancers, utilizing a unique approach that combines advanced science with patient-centric strategies. Nuvation Bio\u2019s lead candidate, NUV-868, is a selective inhibitor of the protein CDK2, which plays a crucial role in the progression of cancer. This candidate is currently undergoing clinical trials to evaluate its efficacy and safety in patients with specific cancer types. The company emphasizes a commitment to science and innovation, striving to leverage cutting-edge research to bring transformative therapies to market. With a team of experienced professionals from top pharmaceutical companies and academic institutions, Nuvation Bio is well-positioned to make significant contributions to cancer treatment and improve the lives of patients worldwide.",
    "industry": [
        "Biopharmaceuticals",
        "Healthcare"
    ],
    "headquarters": "New York, New York, USA",
    "founded": "2018",
    "website": "https://www.nuvationbio.com",
    "ceo": "David Hung",
    "social_media": {
        "twitter": "https://twitter.com/NuvationBio",
        "linkedin": "https://www.linkedin.com/company/nuvationbio/"
    },
    "investor_relations": "https://investors.nuvationbio.com",
    "key_executives": [
        {
            "name": "David Hung",
            "position": "CEO"
        },
        {
            "name": "Alison Lawton",
            "position": "President and COO"
        }
    ],
    "product_categories": [
        {
            "category": "Oncology Pipeline",
            "products": [
                "NUV-868"
            ]
        }
    ],
    "seo": {
        "meta_title": "Nuvation Bio Inc. | Innovative Cancer Therapies",
        "meta_description": "Nuvation Bio Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative cancer therapies. Explore our pipeline and commitment to transforming cancer treatment.",
        "keywords": [
            "Nuvation Bio",
            "Biopharmaceuticals",
            "Cancer Treatment",
            "NUV-868",
            "Clinical Trials"
        ]
    },
    "faq": [
        {
            "question": "What is Nuvation Bio known for?",
            "answer": "Nuvation Bio is known for developing innovative therapies for cancer treatment."
        },
        {
            "question": "Who is the CEO of Nuvation Bio?",
            "answer": "David Hung is the CEO of Nuvation Bio Inc."
        },
        {
            "question": "Where is Nuvation Bio headquartered?",
            "answer": "Nuvation Bio is headquartered in New York, New York, USA."
        },
        {
            "question": "What are Nuvation Bio's main products?",
            "answer": "Nuvation Bio's main product candidate is NUV-868, which is in clinical trials for cancer treatment."
        },
        {
            "question": "When was Nuvation Bio founded?",
            "answer": "Nuvation Bio was founded in 2018."
        }
    ],
    "competitors": [
        "FGEN",
        "CLVS",
        "XLRN",
        "CRMD"
    ],
    "related_stocks": [
        "PFE",
        "MRK",
        "JNJ",
        "BMY"
    ]
}